CLINICAL_TRIALS ClinicalTrials.gov record update

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06787612
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:00.446592+00:00
Published At: 2026-04-08T00:00:00+00:00
Record Updated At: 2026-04-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-08"
protocolSection.identificationModule.nctId: "NCT06787612"
protocolSection.identificationModule.officialTitle: "Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16\u00d7CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.